2 ASX shares that could be top buy and hold options

Could these ASX shares generate strong returns over the long term?

| More on:
thinking ASX buy idea

Image source: Getty Images

Arguably one of the best ways to generate wealth is to make long term investments. This is because by investing for long periods, it allows you to benefit from compounding.

But which shares would make good buy and hold investment options? Two to consider are listed below. Here’s why they are rated highly:

CSL Limited (ASX: CSL)

CSL is one of the world’s leading biotherapeutics companies and the name behind the CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies, whereas Seqirus is the second largest influenza vaccines business.

Both businesses have been growing strongly in recent years and have been tipped to continue doing so in the future. This is due to their leading therapies and vaccines, increasing demand, and lucrative research and development pipelines.

In respect to the latter, CSL invests in the region of 11% of its sales into its research and development activities each year. This ensures that it has a pipeline of cutting-edge therapies with significant sales potential. One of those is clazakizumab, which is being developed to treat kidney transplant rejection. This product alone could generate peak sales of US$5.4 billion.

UBS currently has a buy rating and $330.00 price target on CSL’s shares.

Xero Limited (ASX: XRO)

Xero is leading cloud-based business and accounting solution provider to small and medium sized businesses. It offers businesses and their advisors a solution that provides deep cloud accounting functionality together with an ecosystem of over 800 third-party app partners to provide valuable access for small businesses to add point solutions where needed.

This offering is resonating extremely well with businesses across the world, underpinning very strong recurring revenue growth in recent years.

Pleasingly, the company still has a significant market opportunity to grow into. Management estimates that its total addressable market is worth NZ$45 billion at present and growing. This compares to FY 2021’s operating revenue of NZ$848.8 million.

Goldman Sachs believes the company is well-positioned for growth, particularly given its international expansion opportunity and its burgeoning app ecosystem. Combined, the broker believes Xero has a multi-decade runway for strong revenue growth.

Goldman Sachs currently has a buy rating and $153.00 price target on its shares.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

James Mickleboro does not own any shares mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. and Xero. The Motley Fool Australia owns shares of and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares